Deactivation by benzodiazepine of the basal forebrain and amygdala in normal humans during sleep: a placebo-controlled [15O]H2O PET study

Am J Psychiatry. 2004 Apr;161(4):748-51. doi: 10.1176/appi.ajp.161.4.748.

Abstract

Objective: The authors' goal was to identify differences in regional brain activity between physiological and benzodiazepine-induced sleep to clarify the brain structures involved in the drug's hypnotic effect.

Method: Using positron emission tomography, they compared regional cerebral blood flow during non-REM sleep in nine volunteers treated with placebo or triazolam, a short-acting benzodiazepine, in a double-blind, crossover design.

Results: Blood flow in the basal forebrain and amygdaloid complexes was lower during non-REM sleep when subjects were given triazolam than when they were given placebo.

Conclusions: The hypnotic effect of the benzodiazepines may be mediated mainly by deactivation of the forebrain control system for wakefulness and also by the anxiolytic effect induced by deactivation of the emotional center.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Amygdala / metabolism*
  • Anti-Anxiety Agents / administration & dosage
  • Anti-Anxiety Agents / pharmacokinetics*
  • Benzodiazepines / administration & dosage
  • Benzodiazepines / pharmacokinetics*
  • Drug Administration Schedule
  • Electroencephalography
  • Functional Laterality / physiology
  • Humans
  • Male
  • Prosencephalon / metabolism*
  • Sleep, REM / drug effects*
  • Tomography, Emission-Computed*

Substances

  • Anti-Anxiety Agents
  • Benzodiazepines